Skip to main content

Our Innovation

Innovation unlocks our full potential, powers our mindset and advances our mission.

Innovation by employees at all levels is the key to achieving our full potential as individuals and as an organization. We embrace the mindset that we are never done, never satisfied, never standing still. Innovation is the call to go higher, faster and farther in our mission to protect and enhance life.

Innovation in Product Development

First vaccine to be licensed using the FDA Animal Rule

When developing medical countermeasures for potential bioterror threats, human challenge studies would not be ethical or feasible. In these cases, FDA may grant approval based on animal efficacy studies once the product is shown to be safe in humans. (Read more about the FDA animal rule)

BioThrax® (Anthrax Vaccine Adsorbed) is the only FDA-licensed vaccine for the prevention of anthrax disease. In 2015, we expanded the indication for BioThrax to include post-exposure prophylaxis against anthrax. This made BioThrax the first vaccine to be licensed using the FDA Animal Rule and marked the culmination of a 10-year collaborative effort between Emergent, BARDA and NIAID.

Innovation in Product Development

First vaccine to be licensed using the FDA Animal Rule

When developing medical countermeasures for potential bioterror threats, human challenge studies would not be ethical or feasible. In these cases, FDA may grant approval based on animal efficacy studies once the product is shown to be safe in humans. (Read more about the FDA animal rule)

BioThrax® (Anthrax Vaccine Adsorbed) is the only FDA-licensed vaccine for the prevention of anthrax disease. In 2015, we expanded the indication for BioThrax to include post-exposure prophylaxis against anthrax. This made BioThrax the first vaccine to be licensed using the FDA Animal Rule and marked the culmination of a 10-year collaborative effort between Emergent, BARDA and NIAID.

Innovation in Manufacturing

Cutting-edge technology for public health preparedness

BARDA has created three public-private partnerships called "Centers for Innovation in Advanced Development and Manufacturing" (CIADM). These Centers were established to develop and manufacture CBRN medical countermeasures to protect public health in medical emergencies. (Read more about this federal initiative)

In 2012, our Bayview Campus (located in Baltimore, MD) was selected by the U.S. government to be one of the three CIADM locations. At the Bayview Campus, we use innovative single-use technology for flexible and rapid manufacturing of vaccines and therapeutics. (Read more about our CIADM)

Innovation in Manufacturing

Cutting-edge technology for public health preparedness

BARDA has created three public-private partnerships called "Centers for Innovation in Advanced Development and Manufacturing" (CIADM). These Centers were established to develop and manufacture CBRN medical countermeasures to protect public health in medical emergencies. (Read more about this federal initiative)

In 2012, our Bayview Campus (located in Baltimore, MD) was selected by the U.S. government to be one of the three CIADM locations. At the Bayview Campus, we use innovative single-use technology for flexible and rapid manufacturing of vaccines and therapeutics. (Read more about our CIADM)